Journal Article

Hemodynamic-GUIDEd management of Heart Failure (GUIDE-HF)

Johnson, Nessa, Sood, Poornima, Lindenfeld, JoAnn, Mehra, Mandeep R., Costanzo, Maria Rosa, Ducharme, Anique, Zile, Michael, Paul, Sara, Maisel, Alan, Desai, Akshay S., Abraham, William T., Adamson, Philip B., Ginn, Greg, Smart, Frank, Sears, Samuel F.

2019

Overview

Hemodynamic-guided heart failure (HF) management using pulmonary artery (PA) pressures reduces HF hospitalizations (HFHs) in previously hospitalized HF patients with New York Heart Association (NYHA) class III symptoms. It remains uncertain whether this approach reduces not only HFHs but all-cause mortality and if benefits extend to patients with NYHA class II and IV HF or to those symptomatic patients with elevated natriuretic peptides without recent HFH. GUIDE-HF is a prospective trial with 2 arms enrolling patients with HF regardless of ejection fraction (EF). The randomized arm is a single-blind, randomized, controlled trial of PA pressure-guided therapy in NYHA class II-IV patients (n = 1,000) with either a previous HFH or elevated natriuretic peptides (B-type natriuretic peptide/NT-pro–B-type natriuretic peptide). All consenting subjects will receive an implantable PA pressure sensor (CardioMEMS HF System) followed by randomization to either a treatment group, managed with provider remote access to the hemodynamic data, or a control group, managed without provider access to these data. Subjects in the control group will receive scheduled, scripted, sham contacts from the study team to maintain blinding as to their study group assignment. The primary study end point is the composite of cumulative HF events and all-cause mortality at 12 months. Secondary end points include quality-of-life and functional assessments. The single arm of the trial is an observational arm in which NYHA class III patients (n = 2,600) with either a previous HFH or elevated natriuretic peptides (but no recent HFH) will be implanted with a PA pressure sensor and observed for occurrence of the primary composite end point of cumulative HF events and mortality at 12 months. This arm will test the hypothesis that hemodynamic-guided care is similarly effective in HF patients enrolled on the basis of elevated natriuretic peptide levels but no recent HFH and those with a recent HFH. GUIDE-HF is the largest clinical trial of hemodynamic-guided HF management across a broad population of HF patients, with a study design and sample size adequate to examine survival, cumulative HF events, quality of life, and functional capacity.

• Publisher: Elsevier Inc,Elsevier Limited
• Subject: Angina / Antagonists / Antibiotics / Anticoagulants / Blood / Blood pressure / Blood Pressure Determination - instrumentation / Blood Pressure Determination - methods / Body mass / Cardiovascular diseases / Cerebral infarction / Clinical trials / Congestive heart failure / Consent / Coronary artery disease / Dialysis / Diuretics / Drugs / Epidermal growth factor receptors / FDA approval / Government programs / Heart diseases / Heart failure / Heart Failure - physiopathology / Heart Failure - therapy / Heart valves / Hemodynamic Monitoring - instrumentation / Hemodynamic Monitoring - methods / Hemodynamics / Humans / Hypertension / Hypotheses / Implantation / Informed consent / Intervention / Intolerance / Intravenous administration / Life expectancy / Life span / Management / Medicare / Mercury / Mortality / Multicenter Studies as Topic / Myocardial infarction / Observational Studies as Topic / Optimization / Patients / Peptides / Pharmacology / Potassium / Pregnancy / Prospective Studies / Pulmonary arteries / Pulmonary Artery - physiology / Pulmonary hypertension / Quality of life / Randomized Controlled Trials as Topic / Reduction / Rheumatic heart disease / Sensors / Single-Blind Method / Sputum / Surgery / Therapy / Thromboembolism / Transplants & implants / Urine